Abecma (idecabtagene vicleucel) / BMS - LARVOL DELTA

Real-world incidence of HLH-like syndromes across CAR T-cell products: A multi-institutional cohort study using the trinetx network (ASH 2025) - "Adult patients (aged ≥18 years) who received one of four U.S. Food and Drug Administration-approved CAR T-cell therapies—axicabtagene ciloleucel (Axi-cel), tisagenlecleucel (Tisa-cel), lisocabtagene maraleucel (Liso-cel), or idecabtagene vicleucel (Ide-cel) between 2017 and 2024 were included. In this large, multi-institutional real-world study, HLH-like syndromes were observed following all CAR T-cell products, with notable variation in incidence by agent. Idecabtagene vicleucel and tisagenlecleucel were associated with the highest 30-day HLH incidence, while axicabtagene ciloleucel had the lowest. These findings highlight the need for product-specific clinical vigilance and may inform post-infusion monitoring protocols."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Hemophagocytic lymphohistiocytosis • Immunology • Inflammation • Rare Diseases

Administration- and adverse event-related costs among patients with multiple myeloma treated with B-cell maturation antigen (BCMA)-targeted agents (ASH 2025) - " A 3-year BIM was developed to evaluate administration and AE-related costs for patients with RRMM and ≥1 prior line of therapy who had received belamaf plus bortezomib and dexamethasone (BVd), belamaf plus pomalidomide and dexamethasone (BPd), cilta-cel, ide-cel, or teclistamab. BVd/BPd had substantially lower administration and AE-related costs vs CAR-T and bispecific therapies, which have high costs mostly due to hospitalizations, premedication, and CRS rates."

Adverse events • Clinical • Hematological Malignancies • Multiple Myeloma • Neutropenia • Thrombocytopenia

Comparative efficacy and safety of bendamustine versus fludarabine and cyclophosphamide as lymphodepleting regimens for CAR-T therapy in hematological malignancies: A systematic review and meta-analysis (ASH 2025) - "Axicabtagene ciloleucel was used in four studies, brexucabtagene autoleucel and tisagenlecleucel in two studies, and lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel in one study each. These findings suggest that bendamustine may serve as a viable alternative LD regimen, especially for patients at high risk of infections. Further prospective studies are warranted to confirm the safety and efficacy of bendamustine compared to standard FluCy regimen."

Retrospective data • Review • Acute Lymphocytic Leukemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Incidence and outcomes of Clostridioides difficile infection in BCMA and CD19 CAR-T cell therapy. (ASH 2025) - "Among individual CAR-T products, the incidence was: for CD19-directed CAR-T, Brexu-cel 5%, Axi-cel 6%, Tisa-cel 5%, and Liso-cel 3%; for BCMA-directed CAR-T, Ide-cel 4% and Cilta-cel 5%. In patients with hematologic malignancies, identifying risk factors and rates of CDI in CAR-T cell therapy is essential for prompt recognition and effective management. Future research on optimizing CDI screening protocol and prevention strategies can help reduce mortality and morbidity in this immunocompromised population."

CAR T-Cell Therapy • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma

Sarcopenia and body composition predict survival and reveal immunometabolic dysfunction via single-cell profiling in anti-BCMA CAR T-treated myeloma (ASH 2025) - " We retrospectively evaluated 108 RRMM patients treated with Idecabtagene vicleucel (ide-cel) or Ciltacabtagene autoleucel (cilta-cel) between 2021 and 2025. Low SAT and sarcopenia emerge as prognostic factors in RRMM CAR T-cell therapy affecting survival, response and immunometabolic profiles. Their quantification through routine imaging enables cost-effective integration into clinical workflows providing an opportunity for early risk stratification. Targeted interventions such as exercise, nutritional support and metabolic optimization may enhance immune fitness and therapeutic outcomes."

Hematological Malignancies • Metabolic Disorders • Multiple Myeloma • Obesity • Sarcopenia • CD8

Title: Association of CAR-T product type with incidence of cancer Therapy–Related cardiac dysfunction (CTRCD) (ASH 2025) - " Five CAR-T products were evaluated for their association with CTRCD: axicabtagene ciloleucel, idecabtagene vicleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, and ciltacabtagene autoleucel. In this retrospective study of CAR-T recipients, the overall incidence of cancer therapy-related cardiac dysfunction (CTRCD) was notable at 39%, with variability observed across CAR-T products. Axicabtagene ciloleucel demonstrated the highest rate of CTRCD, while no events were seen with brexucabtagene autoleucel or ciltacabtagene autoleucel. Despite these trends, statistical analyses did not reveal a significant association between CAR-T product type and CTRCD incidence."

Hematological Malignancies • Immunology • Oncology • Systemic Inflammatory Response Syndrome • IL6

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis (ASH 2025) - "Six CAR T-cell products have been approved by the U.S. Food and Drug Administration (FDA) to date: tisagenlecleucel (Tisa-cel), axicabtagene ciloleucel (Axi-cel), brexucabtagene autoleucel (Brexu-cel), lisocabtagene maraleucel (Liso-cel), ciltacabtagene autoleucel (Cilta-cel), and idecabtagene vicleucel (Ida-cel), for pediatric and adult B-cell acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma, follicular lymphoma and mantle cell lymphoma. Our FAERS analysis reveals distinct patterns of secondary primary malignancies and relapsed diseases following CAR T-cell therapy in real-world settings. The identification of myelodysplastic syndromes, cutaneous neoplasms, and rare T-cell or solid tumors highlights the need for vigilant post-therapy surveillance."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Basal Cell Carcinoma • Brain Cancer • Carcinoid Tumor • Diffuse Large B Cell Lymphoma • Endocrine Cancer • Eye Cancer • Follicular Lymphoma • Gastric Cancer • Glioblastoma • Glioneuronal Tumor • Head and Neck Cancer • Hematological Malignancies • Kaposi Sarcoma • Leiomyosarcoma • Leukemia • Lung Cancer • Lymphoma • Mantle Cell Lymphoma • Merkel Cell Carcinoma • Multiple Myeloma • Myelodysplastic Syndrome • Neuroendocrine Carcinoma • Non-Hodgkin’s Lymphoma • Non-melanoma Skin Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Peripheral T-cell Lymphoma • Rhabdomyosarcoma • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Squamous Cell Skin Cancer • T Cell Non-Hodgkin Lymphoma

Endocrine adverse events following CAR-T cell therapies: A pharmacovigilance analysis in the real-world setting utilizing the faers database (ASH 2025) - "CAR-T products analyzed included axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, ciltacabtagene autoleucel, idecabtagene vicleucel, and lisocabtagene maraleucel. This FAERS-based real-world analysis identifies relevant endocrine toxicities linked to CAR-T therapies, with strongest associations observed for axicabtagene ciloleucel and tisagenlecleucel. Immune-mediated dysfunction in the pituitary and thyroid axes appears most prominent. These findings support the need for increased endocrine monitoring post-CAR-T and suggest a class-wide effect with further prospective study."

Adverse events • CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Cushing’s Disease • Diabetes • Endocrine Disorders • Hematological Malignancies • Immunology • Metabolic Disorders • Nephrology • Renal Disease

The fast off-rate of anito-cel's D-Domain binder contributes to its distinctive pharmacology profile in preclinical models of multiple myeloma (ASH 2025) - "Introduction: B cell maturation antigen (BCMA) directed CAR T-cell therapies have transformed the multiple myeloma (MM) treatment landscape with idecabtagene vicleucel and ciltacabtagene autoleucel approvals in relapsed/refractory MM (RRMM). We determined that anito-cel's D-Domain binder has a faster off-rate, bound to BCMA + target cells with a distinct immune synapse architecture and demonstrated decreased cytokine production while maintaining similar cytotoxicity relative to a dual VHH BCMA CAR T. Anito-cel also maintains its ability to target BCMA variants acquired post BCMA TCEs. Combined, these structural and functional data highlight anito-cel's unique ability to transiently engage BCMA, potentially conferring tumor killing without prolonged inflammation. Emerging crystallography and epitope mapping studies will further substantiate this model."

IO biomarker • Preclinical • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • CSF2 • IFNG • IL2

Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy (ASH 2025) - "72% of the population had diffuse large B-cell lymphoma (DLBCL) and 65% of the cohort received axicabtagene ciloleucel...68% of this group had IgG MM and 52% of the cohort received idecabtagene vicleucel...56% of the ALL cohort received brexucabtagene autoleucel... ALC at time of apheresis and infusion may influence progression/survival status and incidence of CRS/ICANS. ALC at apheresis may be predictive of the quantity of lymphocytes being collected and ALC at infusion may effect CAR-T expansion by impacting the cellular immune environment. These findings were more pronounced in the NHL cohort than in the MM or ALL cohorts, which may reflect the effect of disease specific characteristics as well as the confounder of circulating leukemic cells registering as lymphocytes."

Clinical • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

Therapeutic trade-offs between ide-cel and cilta-cel in RRMM: A meta-analytic comparison of efficacy and adverse events (ASH 2025) - "This meta-analysis highlights key distinctions in both efficacy and safety between Ide-cel and Cilta-cel in patients with relapsed/refractory multiple myeloma. Cilta-cel was associated with a significantly higher overall response rate, while Ide-cel showed greater odds of achieving VGPR. However, Ide-cel also showed a higher risk of CRS and severe thrombocytopenia."

Adverse events • Clinical • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Neutropenia • Thrombocytopenia

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Outpatient administration of idecabtagene vicleucel: Predictors of hospitalization and impact on survival outcomes (ASH 2025) - "87.5% (14/16) of these patients received tocilizumab. Grade 1 ICANS was highest severity observed in 19% (4/21) of patients, requiring treatment with steroids with or without anakinra... Outpatient administration of Ide-cel for RRMM is associated with a high incidence of early CRS and ICANS, often leading to unplanned hospitalizations. Lower baseline albumin and hemoglobin levels, along with elevated ferritin, may help identify patients at higher risk for complications. While these factors correlated with hospitalization risk, they did not predict survival in this small cohort."

Clinical • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma • Pneumonia • Respiratory Diseases

Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting (ASH 2025) - "Among them, six received idecabtagene vicleucel and two received ciltacabtagene autoleucel...Two patients received pomalidomide monotherapy, and six received an elotuzumab-based combination regimen with either pomalidomide or lenalidomide, with or without dexamethasone, as maintenance therapy... Maintenance therapy following CAR T-cell infusion was associated with deepening of response in a subset of our patients (50%) with RRMM. However, the high incidence of infectious complications and hematologic toxicity highlights the need for careful patient selection and monitoring. These preliminary findings suggest that while maintenance may enhance disease control post–CAR T-cell therapy, the risk-benefit balance remains a critical consideration, and infectious complications are a particular concern."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Infectious Disease • Multiple Myeloma • Neutropenia • Respiratory Diseases • Targeted Protein Degradation • CRBN

Impact of renal impairment and lymphodepletion regimen on outcomes after CAR T-cell therapy in relapsed/refractory multiple myeloma (ASH 2025) - "The standard lymphodepletion (LDP) regimen is fludarabine andcyclophosphamide (Flu/Cy), but bendamustine has shown comparable efficacy and lower toxicity rates.Given the renal clearance dependency of fludarabine, bendamustine offers an alternative for patients(pts) with renal impairment. Early N-ICAHT grades differed significantlybetween groups (p=0.002), and early absolute neutrophil count (ANC) nadir was significantly higher in thebendamustine cohort (p<0.001). While there was a significant difference in early T-ICAHT grades (p=0.01),no significant differences were observed regarding late N-ICAHT, early platelet nadir, late T-ICAHT, earlyanemia, early hemoglobin nadir, late anemia, as well as cytokine release syndrome (CRS) or immuneeffector cell-associated neurotoxicity syndrome (ICANS).ConclusionOur findings highlight the safety of bendamustine-based LDP and emphasize the prognostic value ofrenal function in Cilta-cel-treated pts, with the efficacy advantage of..."

CAR T-Cell Therapy • Chronic Kidney Disease • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Nephrology • Renal Disease • CD4

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium (ASH 2025) - "Introduction: The CAR-T therapies ide-cel and cilta-cel are approved for patients (pts) withrelapsed/refractory multiple myeloma (RRMM)...Baseline characteristics were similar for pts with no SPM versus SPM including:age at CAR-T (median 67 vs 65), female (36% vs 43%), Black (13% vs 16%), prior autologous transplant(87% vs 80%), lenalidomide for ≥2 years (31% vs 27%), high risk cytogenetics (23% vs 29%), and knownclonal hematopoiesis (7.5% vs 9.9%)... With a median follow up of 13.1 months, the incidence of developing a SPM following CAR-Tin pts with RRMM was 3.6%, of which approximately half were myeloid malignancies. There was nodifference in SPM incidence when comparing the two CAR-T products. Pts treated with ≥2 alkylator LOThad a higher risk of SPM in multivariable analysis and may warrant additional monitoring for SPMdevelopment."

Acute Myelogenous Leukemia • B Cell Lymphoma • Genetic Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Skin Cancer • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Kinetics of circulating multiple myeloma cells (CMMCs) in patients undergoing standard-of-care anti-BCMA chimeric antigen receptor T cell therapy for Relapsed/Refractory multiple myeloma (ASH 2025) - "45 received cilta-cel and 3 ide-cel. Due to excellent outcomes in this cohort, further follow up is neededto assess if baseline CMMC levels or CMMC kinetics are risk factors for treatment failure with CAR Ttherapy. The utility of CMMCs as a method of early relapse detection requires samples from later timepoints and sample collection is ongoing."

CAR T-Cell Therapy • Clinical • IO biomarker • Breast Cancer • Hematological Malignancies • Multiple Myeloma • Solid Tumor • KRAS • PTPRC • SDC1

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma (ASH 2025) - "We demonstrate that the two CAR-T products differ not only in toxicity profile but also inCAR-T expansion dynamics, with cilta-cel associated with a higher peak. We did not observe a significantcorrelation between CAR-T levels and most specific toxicities within subgroups, likely due to small samplesize. However, there were notable trends for certain toxicities within the cilta-cel group for expansion,ALC, and inflammatory markers."

CAR T-Cell Therapy • IO biomarker • Gastrointestinal Disorder • Hematological Malignancies • Inflammation • Multiple Myeloma • CD4 • CD8 • CRP

Novel allogeneic BCMA CAR-expressing iNKT cells with PD1 deletion demonstrate superior tumor control in a multiple myeloma preclinical model (ASH 2025) - "Background : Two BCMA-directed CAR-T cell products, Idecabtagene vicleucel (ide-cel) and Ciltacabtageneautoleucel (cilta-cel), have received FDA approval for use in patients with relapsed/refractory multiplemyeloma (R/R MM) and demonstrated outstanding benefit. We are advancing a novel allogeneic CAR-iNKT cell therapy by integrating our proprietaryPD-1 intracellular retention technology to boost the efficacy of adoptive cell treatment. Leveraging aniNKT platform naturally devoid of alloreactivity, we enable rapid engineering and expansion of an "off-the-shelf" CAR product. Additionally, the inherent capabilities of iNKT cells, such as bone marrow homingand BCMA targeting, reinforced by CD1d and NK receptor-ligand interactions, offer unique advantages.We believe this approach could deliver significant benefits to patients with R/R MM, surpassing theefficacy of existing therapies."

Preclinical • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • PD-1

Clonoseq MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma. (ASH 2025) - " We retrospectively analyzed 171 MM patients treated with SOC BCMA CAR-T, idecabtagenevicleucel (110/171) and ciltacabtagene autoleucel (cilta-cel), at Moffitt Cancer Center from May 2021 toSeptember 2024 who had trackable clonotype and D90 NGS-MRD testing...Rates ofcytokine release syndrome, immune effector cell-associated neurotoxicity (ICANS), non-ICANSneurotoxicity, steroid, tocilizumab or anakinra use, intensive care unit admission, and hospital stay werecomparable between groups... In this large SOC cohort of MM patients, NGS-MRD negativity at D90 post BCMA CAR-T wasindependently associated with improved PFS and OS. Our data support the use of D90 NGS-based MRDtesting as a prognostic tool for survival outcomes and the development of MRD-driven interventions postCAR-T."

CAR T-Cell Therapy • Clinical • IO biomarker • Minimal residual disease • Hematological Malignancies • Multiple Myeloma

Longitudinal immune monitoring in patients treated with CD19 and BCMA CAR-T cells using standardized 8‑color flow cytometry panel reveals substantial differences among products kinetics and persistence (ASH 2025) - "Currently approved products target CD19 (axi-cel, brexu-cel, tisa-cel, liso-cel)and BCMA (cilta-cel, ide-cel). This is the first study comprehensively comparing CAR-T and non-CAR-T cell kinetics acrossdifferent CAR-T products targeting CD19 and BCMA using a specialized flow cytometry panel. Distinctpeak kinetics and persistence patterns were observed, with cilta-cel showing higher peaks and rapiddisappearance by M3, accompanied by B-cell recovery, while axi-cel tends to persist for longer timeperiod in a subset of patients, with prolonged B cell aplasia. In axi-cel patients, greater CAR-T expansionwas associated with higher toxicity but also improved response and PFS."

CAR T-Cell Therapy • Clinical • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • CD20 • CD8 • NCAM1 • PTPRC

A post-marketing pharmacovigilance analysis of cardiotoxicities following chimeric antigen receptor T-cell therapy using the FDA adverse event reporting system (ASH 2025) - "Therefore, a post-marketing pharmacovigilance analysis of the cardiac AEs reported to the FDAAdverse Event Reporting System (FAERS) for each CAR-T product was conducted to address thisknowledge gap. All individual case safety reports of cardiac AEs listing any of the approved CAR-T therapies[Tisagenlecleucel (Tisa-cel), Axicabtagene ciloleucel (Axi-cel), Lisocabtagene maraleucel (Liso-cel),Brexucabtagene autoleucel (Brexu-cel), Idecabtagene vicleucel (Ide-cel), Ciltacabtagene autoleucel (Cilta-cel) and Obecabtagene autoleucel (Obe-cel)] as the suspected drug were identified from the FAERSdatabase... This post-marketing pharmacovigilance analysis highlights patterns of cardiac AEs followingCAR-T therapy. Trends in AEs based on CAR-T product, age, and sex support the ongoing need forvigilance for these unique toxicities. As this study is limited by FAERS reporting bias, prospective studiesto validate these associations and elucidate the underlying mechanisms are needed,..."

Adverse events • CAR T-Cell Therapy • P4 data • Acute Coronary Syndrome • Acute Lymphocytic Leukemia • B Cell Non-Hodgkin Lymphoma • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Hypotension • Leukemia • Lymphoma • Multiple Myeloma • Myocardial Infarction • Non-Hodgkin’s Lymphoma • Thrombosis • ROR1

Association between pre-existing mental health history and higher risk of mental health outcomes post-CAR-t therapy in patients with hematologic malignancies (ASH 2025) - "CAR-T therapies included tisagenlecleucel, brexucabtagene autoleucel, axicabtagene ciloleucel,lisocabtagene maraleucel, idecabtagene vicleucel, and ciltacabtagene autoleucel. This analysis offers a unique perspective on the mental health trajectories of CAR-T therapyrecipients, considering their pre-treatment mental health status. The findings indicate that individualswithout prior mental health disorders exhibited a substantially lower risk of developing mental healthissues following CAR-T therapy. In contrast, patients with pre-existing mental health comorbiditiesdemonstrated a statistically significant increase in the incidence of mood disorders, anxiety, andbehavioral syndromes post-treatment."

Clinical • HEOR • CNS Disorders • Hematological Malignancies • Mood Disorders • Oncology • Psychiatry

CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities. (ASH 2025) - "CirAE are associated with elevated CARTexpansion in the first two weeks, suggesting that modulating CART-BCMA proliferation without affectingCART effector function could improve safety and expand therapeutic use. We retrospectively analyzed a cohort of 198 multiple myeloma (MM) patients treated with CART-BCMA (idecabtagene vicleucel [ide-cel] and ciltacabtagene autoleucel [cilta-cel]) at the University ofPennsylvania (June 2021-December 2024) to identify predictors of CirAE and to investigate themechanisms underlying the early onset of CirAE...Finally, CCR5 knockout impaired antigen-driven proliferation and rendered CART insensitive to maraviroc, confirming on-target specificity. We identified the IL‑15–CCL5–CCR5 circuit as a key driver of CART-BCMA proliferation inCirAE and demonstrated that CCR5 blockade safely restrains CART-BCMA expansion while preservingtheir anti‑myeloma activity. These findings support CCR5-directed targeted strategies to selectivelymodulate CART..."

IO biomarker • CNS Disorders • Gastrointestinal Disorder • Hematological Malignancies • Multiple Myeloma • CD4 • CD8 • CXCL10 • CXCL9 • GZMB • IL15 • IL2 • IL7 • LAMP1

Impact and predictors of icans on survival in lymphoma and myeloma patients treated with CAR T cell therapy (ASH 2025) - "Most NHLpatients received Axi-cel (73%), while MM patients received Ide-cel (54%) or Cilta-cel (46%). ICANS occurs in 40% of CAR T-cell recipients, with similar incidence in NHL and MM butgreater severity in NHL. Its occurrence, early onset, and prolonged duration are associated withsignificantly reduced OS, regardless of disease type. Age ≥70 and high CRP further identify high-riskpatients."

CAR T-Cell Therapy • Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma